Introduction
Craniofacial deformities, such as cleft palate, are among the most common congenital birth defects in humans (1) . Altered TGF-β signaling causes syndromic and nonsyndromic cleft palate. For instance, mutations in the genes for TGF-β receptor type I or type II (TGFBR1 [also known as ALK5] or TGFBR2, respectively) are associated with Loeys-Dietz syndrome (previously called Marfan syndrome type II) in humans, which can manifest with craniofacial malformations, including cleft palate, craniosynostosis, hypertelorism, and vascular defects (2, 3) . In addition, mutations in FBN1, which encodes an elastic extracellular matrix protein called fibrillin 1, lead to excessive TGF-β signaling and cause Marfan syndrome, which exhibits clinical phenotypes similar to those of Loeys-Dietz syndrome (4) (5) (6) . Furthermore, individuals with DiGeorge syndrome, which results from a variably sized deletion on chromosome 22 (del22q11), exhibit altered TGF-β signaling (7) (8) (9) . Thus, TGF-β signaling is crucial in regulating craniofacial development, and altered TGF-β signaling leads to multiple malformations in humans. Interestingly, these studies show that TGF-β signaling is elevated in patients with these syndromes. Nevertheless, we still do not have a clear understanding of the TGF-β signaling mechanism and its functional impact on craniofacial development in patients with mutations in TGFBR genes.
TGF-β signaling mediates a wide range of biological activities in development and disease. TGF-β ligands signal through heterodimeric type I and type II receptors (TGF-β receptor type I [TβRI, also known as ALK5 and TGFBR1] and TβRII) that are members of the serine/threonine kinase family. To date, overwhelming evidence supports the notion that both TβRII and TβRI are indispensable in eliciting the biological response of TGF-β (10) . The third member of the TGF-β receptor family, TβRIII (β-glycan), has high binding affinity for TGF-β2 and may be critical for keeping TGF-β at the cell surface for the TβRI/TβRII complex (11) . TβRIII may be required for optimal TGF-β2 function during development. Despite the fact that it is missing an intracellular kinase domain, TβRIII plays a crucial role in regulating embryonic development, because loss of Tgfbr3 results in an early embryonic lethal phenotype in mice (12) .
Tgfbr1/Alk5, Tgfbr2, and Tgfbr3 are expressed in the developing craniofacial region, and loss of Tgfbr1/Alk5 or Tgfbr2 results in an array of craniofacial deformities, clearly indicating the functional significance of TGF-β signaling in regulating craniofacial development in mice (13) (14) (15) (16) . In the canonical TGF-β signaling pathway, the TβRII/TβRI complex activates the receptor-regulated SMADs, which form a transcriptional regulatory complex with SMAD4, move into the nucleus, and control downstream target gene expression (11) . In parallel, our recent study showed that ectodermal SMAD4 and p38 are functionally redundant in mediating TGF-β signaling and demonstrated the significance of the SMAD-independent pathway in regulating craniofacial development (17) .
In order to test the functional significance of TGF-β signaling in regulating the fate of cranial neural crest (CNC) cells, we generated a mutant animal model, in which loss of Tgfbr2 in CNC cells leads to an array of craniofacial deformities, including cleft palate (13) . We have shown that CNC cells have a cell autonomous requirement for TβRII to regulate cell proliferation during palatogenesis. In the present study, we investigated the molecular mechanism of TGF-β signaling-mediated palatogenesis by analyzing TGF-β downstream target genes using Tgfbr2 fl/fl ;Wnt1-Cre mice. Surprisingly, we detected an elevation of TGF-β2 expression that is responsible for the cell proliferation defect and cleft palate in Tgfbr2 mutant mice. Our study demonstrates that elevated TGF-β2 activates an alternative TGF-β signaling pathway through the TβRI/TβRIII receptor complex and induces a SMAD-independent TNF receptor-associated factor 6/TGF-β-activated kinase 1/p38 (TRAF6/TAK1/p38) signaling cascade in the absence of TβRII. Importantly, genetic manipulation of this alternative TGF-β signaling prevents craniofacial deformities in Tgfbr2 mutant mice and offers what we believe to be a unique opportunity for the prevention of craniofacial malformations.
Results

Identification of TGF-β downstream target genes during palatogenesis.
Mice lacking Tgfbr2 in CNC cells exhibit an array of craniofacial deformities, including cleft palate (13) . We have shown that CNC cells have a cell autonomous requirement for TβRII to regulate cell proliferation during palatogenesis. To investigate the mechanism of altered TGF-β signaling in Tgfbr2 mutant mice, we performed global gene expression analyses of the palatal tissue of Tgfbr2 fl/fl ;Wnt1-Cre mice and Tgfbr2 fl/fl control mice at E14.5 (during palatal fusion, n = 5 per genotype) and examined the downstream consequences of dysfunctional TGF-β signaling. In this comparison, we uncovered 293 probe sets representing transcripts that were differentially expressed (≥1.5-fold, <5% false discovery rate [FDR] ), 149 probe sets that were more abundant in Tgfbr2 fl/fl ;Wnt1-Cre mice (Supplemental Table 1 ; supplemental material available online with this article; doi:10.1172/ JCI61498DS1), and 144 probe sets that were more abundant in Tgfbr2 fl/fl control mice (Supplemental Table 2 ). The genes identified as altered in Tgfbr2 fl/fl ;Wnt1-Cre mice were consistent with cell proliferation defects, with significant reductions in the levels of transcripts related to cell cycle control, mitosis, and microtubule-based cell division and with enrichment for transcripts related to the negative regulation of cellular proliferation (Supplemental Table 2 ).
In a focused analysis of Tgfb and Tgfbr gene family member expression, we discovered that Tgfb2 and Tgfbr3 transcript levels were more abundant in the palates of the Tgfbr2 fl/fl ;Wnt1-Cre mice than in those of the control (Table 1 ). The microarray data was validated by quantitative RT-PCR analysis of TGF-β ligands and receptors ( Figure 1A ). As expected, TGF-β2 and TβRIII protein levels were also upregulated in the palatal mesenchyme of Tgfbr2 fl/fl ; Wnt1-Cre mice at E14.5 ( Figure 1B) . TGF-β2 has a high affinity for TβRIII, a unique feature that distinguishes TGF-β2 from other TGF-β ligands (18, 19) . In in vitro studies, TGF-β isoforms differentially bind to TGF-β receptors and play crucial nonoverlapping roles during craniofacial development (20, 21) .
To identify proteins relevant to dysfunctional TGF-β signaling after the loss of Tgfbr2, we analyzed protein extracts from cultured mouse embryonic palatal mesenchymal (MEPM) cells of Tgfbr2 fl/fl (control) mice and Tgfbr2 fl/fl ;Wnt1-Cre mice (Supplemental Figure 1 and Supplemental Table 3 ). We found that β-spectrin, an adaptor protein of TβRI, was upregulated in Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells (Figure 2A , Supplemental Figure 1C , and Supplemental Table 3 ). β-Spectrin is associated with TGF-β receptors, and loss of β-spectrin leads to disruption of TGF-β signaling by SMAD proteins in mice, indicating that β-spectrin is involved in SMAD-dependent TGF-β signaling (22) . β-Spectrin knockout mice exhibit a phenotype similar to that of Smad2 +/-;Smad3 +/-mutant mice, with midgestational death due to gastrointestinal, liver, neural, and heart defects (22) . β-Spectrin expression was detectable in primary MEPM cells and palatal mesenchyme of both Tgfbr2 fl/fl ;Wnt1-Cre and control mice but appears to be increased in Tgfbr2 fl/fl ;Wnt1-Cre mice ( Figure 2 , B and C). Consistent with its ability to interact with TGF-β receptors, β-spectrin was mainly localized at the cell membrane in Tgfbr2 fl/fl ;Wnt1-Cre mice ( Figure 2B, arrows) .
Similarly, 14-3-3ζ/δ and phosphorylated 14-3-3 were elevated in Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells compared with those in control cells (Figure 2A ). 14-3-3 is a TβRI-interacting protein that is phosphorylated by p38 MAPK α, β, γ, or δ (MAPK14/11/12/13) and plays a key role in protein targeting and protein domain- specific binding (23). 14-3-3 expression appeared to be increased in Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells, and phosphorylated 14-3-3 was increased in Tgfbr2 fl/fl ;Wnt1-Cre mice ( Figure 2D ). Notably, we found elevated 14-3-3 expression in the palatal mesenchyme of Tgfbr2 fl/fl ;Wnt1-Cre mice compared with that in controls (Figure 2E) . Consistent with these results, p38 MAPK was activated only in Tgfbr2 mutant MEPM cells but not in control cells ( Figure  2F ). To investigate p38 MAPK-mediated 14-3-3 phosphorylation Figure 2G ). Alternative TGF-β signaling pathway in the absence of TβRII. To analyze the mechanism of signaling initiated in the absence of Tgfbr2, we performed coimmunoprecipitation assays using anti-TβRI, TβRIII, and β-spectrin antibodies and extracts of control and Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells ( Figure 3A) . β-Spectrin was coimmunoprecipitated with TβRIII and TβRI antibodies in Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells ( Figure 3A) . Although the interaction between TβRI and β-spectrin was not altered in Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells compared with that in control cells, TβRIII was more abundantly coimmunoprecipitated by β-spectrin antibody in Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells, and vice versa, indicating that β-spectrin stably bound to TβRI and more abundantly bound to TβRIII in the absence of TβRII ( Figure 3A ). To validate that the interaction between β-spectrin and TβRIII is dependent on TGF-β2, we performed coimmunoprecipitations after treatment with TGF-β2. Although the interaction between TβRI and TβRIII was induced by TGF-β2 in both control and Figure 3B ). Furthermore, we performed cross-linking analysis to test whether TGF-β2 binds to TβRI and TβRIII in the absence of Tgfbr2 using radioactive TGF-β2 ligands. In Tgfbr2 fl/fl control MEPM cells, radioactive TGF-β2 ligands (12.5 kDa) bind to TβRI (53 kDa), TβRII (70 kDa), and TβRIII (100-200 kDa, highly glycosylated molecule) and form the ligand-receptor complexes of TβRI::TGF-β2 (65.5 kDa), TβRII:: TGF-β2 (82.5 kDa), and TβRIII::TGF-β2 (112.5-212.5 kDa) ( Figure  3C ). In contrast, radioactive TGF-β2 was more abundantly crosslinked with TβRIII and TβRI/TβRIII in Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells, and complexes of TβRIII::TβRI::TGF-β2 (165.5-265.5 kDa), TβRIII::TGF-β2 (112.5-212.5 kDa), and TβRI::TGF-β2 (65.5 kDa), but not TβRII::TGF-β2 (82.5 kDa), were detectable ( Figure 3C ). To confirm our findings further, we performed immunoprecipitationcross-linking analysis ( Figure 3D ). We found that TGF-β2 can bind to TβRI and TβRIII, but not TβRII, in Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells and forms a complex with TβRIII and TβRIII/TβRI ( Figure  3 , D and E). Collectively, our data indicate that a TGF-β2/TβRIII/ TβRI complex forms in the absence of Tgfbr2 and likely transduces TGF-β signaling in palatal mesenchymal cells.
TGF-β signals through a receptor complex of both TβRII and TβRI, causing phosphorylation of SMAD proteins (11, 24) . We found that SMAD-dependent TGF-β signaling was compromised in Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells ( Figure 3F ). In parallel, patients with TGFBR2 mutations show elevated TGF-β signaling (3, 25) . We hypothesized that elevated TGF-β2 levels in Tgfbr2 mutant cells initiate an intracellular signal in the absence of Tgfbr2, most likely via a SMAD-independent p38 MAPK pathway, using a hitherto unidentified mechanism.
MAPK kinase kinase 7 (MAP3K7), also known as TAK1, was originally identified as an activator of TGF-β-induced p38 activation (26) . SMAD-dependent TGF-β signaling is compromised in the palates of Tgfbr2 fl/fl ;Wnt1-Cre mice ( Figure 3F ). Based on our observation that p38 MAPK was activated in the palates of Tgfbr2 fl/fl ;Wnt1-Cre mice, TGF-β2 may activate SMAD-independent TGF-β signaling through a TAK1/p38 MAPK cascade. We found that TAK1 activation was upregulated in Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells, which correlated with p38 MAPK activation ( Figure 3F ). In contrast, although TAK1 is also involved in BMP signaling, BMP signaling was not altered in Tgfbr2 mutant cells (Supplemental Figure 3) , indicating that BMP signaling was not responsible for TAK1/p38 MAPK activation. To test our model that loss of TβRII leads to the activation of a TAK1/p38 pathway, we performed siRNA knockdown of Tgfbr2 in wild-type MEPM cells. Indeed, reduction of Tgfbr2 in wild-type MEPM cells activated a TAK1/p38 MAPK cascade ( Figure 4A ). In addition, reintroduction of Tgfbr2 in Tgfbr2 mutant cells reversed ectopic TAK1/p38 MAPK activation ( Figure 4B ), suggesting that compromised TβRII expression is crucial for the TAK1/p38 MAPK activation. TAK1 can bind to the TAK-associated binding protein 1 (TAB1), TAB2, and TAB3 (27) . The activity of this complex is dependent on the amino-terminal RING domain in the E3 TRAF6 (28) . Therefore, we speculated that the activity of the TAK1/TAB complex might affect p38 MAPK activation in MEPM cells. To test this hypothesis, we performed siRNA knockdown of Tak1 or Tab1 (Supplemental Figure 4) . siRNA knockdown for Tak1, but not Tab1, blocked p38 MAPK activation in Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells, indicating that TAK1 is crucial for p38 MAPK activation.
We next addressed the possibility that disruption of Tgfbr2-mediated signaling might lead to signaling through an alternative type II receptor. However, we detected no change in the expression of other type II receptors in the TGF-β family (Bmpr2, Acvr2a, Acvr2b) in Tgfbr2 mutant mice (Supplemental Tables 1 and 2) , and siRNA knockdown of Bmpr2, Acvr2a, and Acvr2b had no effect on the TAK1 activation (Supplemental Figure 5) . To explore the downstream target of the TβRIII/TβRI signaling complex in the absence of TβRII, we performed siRNA knockdown for Tgfbr3 and Tgfbr1. We found that siRNA knockdown for Tgfbr3 and Tgfbr1 resulted in a reduction of the ectopic TAK1 activation in Tgfbr2 mutant cells, indicating that lack of TβRII activates the TAK1 cascade through the TβRI/TβRIII complex (Supplemental Figure 6) .
Previous studies indicated that MAPK pathways (p38 and c-Jun NH 2 -terminal kinase [JNK1, JNK2, and JNK3, also known as MAPK8, MAPK9, and MAPK10, respectively]) are activated by SMAD-independent pathways via lys63 ubiquitination (K63 ubiquitination) and phosphorylation of TAK1 after binding of TGF-β ligands (29, 30) . TβRI induces ubiquitination of TRAF6 on K63 after the binding of TGF-β. TRAF6-induced polyubiquitination of TAK1 leads to TAK1 activation, resulting in "juxtaposition-induced autophosphorylation" (29) . Therefore, we investigated K63 ubiquitination of TRAF6 and TAK1 in Tgfbr2 mutant cells. We found that K63 ubiquitination of both TRAF6 and TAK1 was upregulated in Tgfbr2 fl/fl ;Wnt1-Cre MEPM cells ( Figure 4C) . Thus, our results show that, in the absence of Tgfbr2, TGF-β2 forms a complex with TβRIII/ TβRI/β-spectrin and induces a TRAF6/TAK1/p38 MAPK signaling cascade in the palatal mesenchyme ( Figure 4D) .
Rescue of cleft palate by manipulation of the alternative TGF-β signaling pathway. Our previous study showed that loss of Tgfbr2 results in cleft palate with reduced CNC cell proliferation in the palatal mesenchyme (13) . In this current study, we show that elevated Figure 5B) . In order to test the hypothesis that activation of alternative TGF-β signaling in Tgfbr2 fl/fl ;Wnt1-Cre mice depends on the noncanonical TGF-β signaling mediated by TβRI/TβRIII, we cultured palates with a NAb for TβRIII ( Figure 5, C and D) . The cell proliferation defect was rescued by treatment with the NAb for TβRIII in the ex vivo organ culture system, whereas cell proliferation was not affected in control samples treated with a TβRIII NAb ( Figure 5C ). To examine the requirements of TAK1 and p38 MAPK activation for the cell proliferation defect in Tgfbr2 fl/fl ;Wnt1-Cre palates, we cultured palates with a TAK1 or p38 MAPK inhibitor, (5Z)-7-Oxozeaenol or SB203580, respectively, and found that the cell proliferation defect was also rescued (Figure 5 , E−G).
Previous reports suggest that ubiquitination of TRAF6 by TGF-β is independent of TβRI kinase activity (29) . Therefore, we tested whether TβRI kinase activity is necessary for the activation of TAK1/p38 MAPK and inhibition of TβRI kinase activity can rescue a defect in cell proliferation in Tgfbr2 fl/fl ;Wnt1-Cre palates in the ex vivo organ culture system. An inhibitor of TβRI kinase, A83-01 or SB431542, failed to rescue the cell proliferation defect in Tgfbr2 fl/fl ;Wnt1-Cre palates, consistent with the ectopic noncanonical TGF-β signaling being independent of TβRI kinase activity ( Figure 5 , H and I, and data not shown). Thus, elevated TGF-β2 triggers a SMAD-independent TAK1/p38 MAPK signaling cascade via a TβRI/TβRIII complex in the absence of TβRII and adversely affects CNC cell proliferation during palate formation.
Increased TGF-β2 seems to be a trigger for alternative TGF-β signaling activation. Therefore, reduction of TGF-β2 expression may lead to a rescue of cleft palate in Tgfbr2 fl/fl ;Wnt1-Cre mice. To test this hypothesis further, we took an in vivo approach and generated Tgfbr2 fl/fl ;Wnt1-Cre;Tgfb2 +/-mice in order to reduce TGF-β2 ligand expression level. Indeed, Tgfbr2 fl/fl ;Wnt1-Cre;Tgfb2 +/-mice formed normal palates, with 82.5% phenotype penetrance (33 out of 40 mice had normal palates), although they still exhibited a calvaria defect and small mandible (Figure 6A and Supplemental Figure 7A ). Histological analysis showed that the growth and elevation of the palatal shelf in Tgfbr2 fl/fl ;Wnt1-Cre;Tgfb2 +/-mice was similar to that in the control at E14.5 ( Figure 6B ). At E16.5, palatal shelves fused normally in Tgfbr2 fl/fl ;Wnt1-Cre;Tgfb2 +/-mice ( Figure 6B ). At birth, the palatal processes of the maxilla and the palatine bones were partially rescued in Tgfbr2 fl/fl ;Wnt1-Cre;Tgfb2 +/-mice compared with those in the control, whereas there was little palatine bone formation in Tgfbr2 fl/fl ;Wnt1-Cre mice ( Figure 6C) .
At the molecular level, the upregulated phosphorylated p38 MAPK and phosphorylated 14-3-3 expression in Tgfbr2 fl/fl ;Wnt1-Cre palates was restored to control levels in E14.5 Tgfbr2 fl/fl ;Wnt1-Cre;Tgfb2 +/-palates ( Figure 6D ). Cell proliferation activity in the CNC-derived palatal mesenchyme was restored to control levels in Tgfbr2 fl/fl ;Wnt1-Cre;Tgfb2 +/-palates ( Figure 6, E and F) . Thus, reducing the TGF-β2 level reversed the activation of p38 MAPK signaling and restored cell proliferation in the palatal mesenchyme of Tgfbr2 fl/fl ;Wnt1-Cre mice.
In our model, TGF-β2-mediated TAK1/p38 MAPK is activated through TβRI. In order to test that activation of alternative TGF-β signaling in Tgfbr2 fl/fl ;Wnt1-Cre mice depends on the presence of TβRI, we generated Tgfbr2 fl/fl ;Wnt1-Cre;Alk5 fl/+ mice ( Figure 7 and Supplemental Figure 7B Figure 8) . Thus, our findings indicate that SMAD-independent, TRAF6/TAK1/p38 MAPK activation mediated through TβRI/TβRIII is responsible for the CNC cell proliferation defect and failure of palatal fusion in Tgfbr2 fl/fl ;Wnt1-Cre mice.
Discussion
TGFBR1 and TGFBR2 mutations have been reported in humans with craniofacial malformations and/or vascular abnormalities (2, 3, (31) (32) (33) (34) . The majority are missense substitutions or nonsense mutations in exon 4 of TGFBR1 and exons 4-7 of TGFBR2 that are predicted to disrupt the kinase domain (34, 35) . Our findings may be relevant in human disease, given that altered TGF-β signaling is implicated in multiple congenital malformations and syndromes in humans. Our observation that TGF-β2 and TβRIII expression is elevated in the palatal mesenchyme of Tgfbr2 fl/fl ;Wnt1-Cre mice led to our discovery of an alternative TGF-β signaling mechanism in the absence of TβRII that is detrimental to craniofacial morphogenesis. Specifically, our study shows that elevated TGF-β2 signals through a TβRI/TβRIII complex to induce a SMAD-independent TRAF6/TAK1/p38 signaling cascade and results in cleft palate in Tgfbr2 mutant mice. This is an important advancement in our understanding of the mechanism of TGF-β signaling. Previous studies suggested that TβRIII appears to be dispensable for TGF-β− mediated signal transduction, because it lacks an intracellular domain and most cells that lack functional TβRIII still respond to TGF-β (12, 36) . However, these studies did not consider how TGF-β signals in the absence of TβRII. Furthermore, TβRIII is required for murine somatic development, because loss of Tgfbr3 results in an early embryonic lethal phenotype (12) . In this study, we show that alternative TGF-β signaling can be activated through the TβRI/TβRIII complex, which in turn activates the TRAF6/ TAK1/p38 MAPK signaling cascade to inhibit CNC-derived palatal mesenchymal cell proliferation and cause cleft palate.
Although Tgfb2 haploinsufficiency rescued the CNC cell proliferation defect and cleft palate in Tgfbr2 fl/fl ;Wnt1-Cre mice, calvarial and mandibular defects were not rescued. In contrast, Tgfbr1/Alk5 haploinsufficiency completely rescued the CNC cell proliferation defect as well as palatal fusion and mostly rescued calvarial, maxillary, and mandibular defects in Tgfbr2 fl/fl ;Wnt1-Cre mice. One possible explanation is that TGF-β ligands other than TGF-β2 can signal through the TβRI/TβRIII complex to cause adverse effects on craniofacial development (Supplemental Figure 9) . Therefore, a reduction of TGF-β2 signaling alone does not prevent these developmental defects, but a reduction of Tgfbr1/Alk5 does. This reasoning is supported by the finding that almost all craniofacial defects, such as cleft palate, microglossia, small mandible, and calvaria defects, are rescued in Tgfbr2 fl/fl ;Wnt1-Cre;Alk5 fl/+ mice. It is important to note that alternative TGF-β signaling involving TβRI/TβRIII is a widely used mechanism and can affect multiple craniofacial organogeneses during development.
The lack of phenotype rescue other than cleft palate in Tgfbr2 fl/fl ; Wnt1-Cre;Tgfb2 +/-mice could also be explained as the result of the CNC-derived palatal mesenchyme being more sensitive than other tissues to the level of noncanonical TGF-β signaling. In support of this theory, progenitor cell differentiation into hepatocytes and biliary cells is dependent on a gradient of TGF-β signaling (37) . It is conceivable that TGF-β levels, in conjunction with Tgfbr activity, differentially modulate distinct signaling pathways that control unique sets of downstream target genes.
The fact that Alk5 fl/fl ;Wnt1-Cre mice exhibit more severe developmental defects than Tgfbr2 fl/fl ;Wnt1-Cre mice suggests that the TβRI may mediate signals from additional members of the TGF-β family (other than TGF-β1, TGF-β2, and TGF-β3) and regulate downstream target genes during craniofacial development. The gene expression pattern of TGF-β ligands and receptors may also contribute more widespread craniofacial malformations in Tgfbr1/ Alk5 mutant mice. We found that there is increased p38 signaling in Tgfbr2 fl/fl ;Wnt1-Cre mice and are differentially affected downstream signaling mediators in Alk5 fl/fl ;Wnt1-Cre mice (J. Iwata et al., unpublished observations), suggesting that noncanonical TGF-β signaling may be controlled via multiple molecular mechanisms during craniofacial development. In parallel, we found that there is no activation of p38 signaling in Alk5 fl/fl ;Wnt1-Cre mice. Further studies are necessary to explore the TGF-β signaling mechanism in the absence of Alk5 during embryonic development.
Recent studies revealed that noncanonical TGF-β signaling is also activated in some physiological (17, 38, 39) and pathological conditions, including Marfan and Loeys-Dietz syndromes (25, 40) . Previous reports have shown that the p38 MAPK activation mediated by TGF-β is able to signal through a kinase-dead TβRI or constitutively active TβRI in the presence of TβRII in cell lines (29, 30) . In contrast, this current study shows that noncanonical TGF-β signaling in the palatal mesenchyme is activated even in the absence of TβRII and results in cleft palate. We found that a low level of activation of noncanonical TGF-β signaling is induced in wild-type MEPM cells, suggesting that some TβRI/TβRII complex may also control p38 MAPK activation in the palatal mesenchyme during normal palate formation.
Previous studies indicate that TGF-β can signal only through TβRI/TβRII complex. In response to TGF-β binding, the cytoplasmic domains of the type I receptors are phosphorylated by the constitutively active type II receptor kinase (41, 42) . TβRII kinase activity is crucial for the activation of TβRI. In this study, we have demonstrated that TβRI/TβRIII complex without TβRII mediates elevated TGF-β2 signaling without requiring the kinase activity of TβRI, consistent with the previous study indicating that TAK1/ p38 MAPK activation is independent of TβRI kinase activity (29) .
A haploinsufficiency of Tak1 in Tgfbr2 mutant mice (Tgfbr2 fl/fl ; Wnt1-Cre;Tak1 fl/+ mice) results in reduced p38 MAPK activation and rescues the craniofacial abnormalities, including cleft palate, consistent with ectopic TAK1/p38 MAPK activation being responsible for these developmental defects in Tgfbr2 mutant mice. In addition, siRNA knockdown for Tak1 inhibited p38 MAPK activation. The TAK1 kinase inhibitor (5Z)-7-Oxozeaenol also blocked p38 MAPK activation and rescued the cell proliferation defect in Tgfbr2 fl/fl ; Wnt1-Cre palates in the ex vivo organ culture system. Thus, TAK1
is crucial for the activation of alternative TGF-β signaling in the absence of TβRII. Regarding the p38 MAPK activity, SB203580 is a selective inhibitor of p38 MAPK, and it inhibits the activation of downstream targets such as 14-3-3. SB203580 inhibits p38 catalytic activity by binding to the ATP-binding pocket but does not inhibit phosphorylation of p38 by upstream kinases. The upregulated p38 phosphorylation in Tgfbr2 mutant cells is partially reversed after treatment with SB203580 (Supplemental Figure 10) , suggesting that p38 activation may be attributed in part to p38 autophosphorylation caused by a feedback mechanism or other stimuli (43) , but mainly results from the TAK1 cascade. Collectively, our data suggest that the TRAF6/TAK1 pathway contributes to 14-3-3 phosphorylation through the activation of p38 MAPK.
14-3-3 proteins comprise a large family of highly conserved acidic polypeptides (44, 45) . Multiple isoforms of 14-3-3 proteins play an essential role in regulating cell proliferation and differentiation and can also interact with a wide variety of proteins related to signal transduction, cell cycle control, vesicular transport, and more (46). 14-3-3 interacts with TβRI and positively regulates TGF-β signaling through TβRI (47). 14-3-3 may thus modulate TGF-β signaling via protein interactions in both SMAD-dependent and -independent pathways and regulate gene expression related to cell proliferation during palatogenesis. These functions will be addressed in future studies.
Our findings that elevated TGF-β2 and ectopic p38 MAPK activation is the molecular mechanism responsible for adversely affecting cell proliferation in the CNC-derived palatal mesenchyme and that reduction of Tgfb2, Tgfbr1/Alk5, or Tak1 rescues cleft palate in Tgfbr2 fl/fl ;Wnt1-Cre mice have the potential for longer-term clinical applications. We propose that elevated TGF-β2 and ectopic TAK1/p38 MAPK activation could serve as biomarkers for identifying individuals with an increased risk of having a child with congenital craniofacial malformations. In addition, our molecular mechanisms could be useful for interpreting the results of large-scale population-based genetic studies aimed at identifying inherited risk factors for craniofacial malformations (48, 49) . Finally, in the longer term, our results could prove useful in efforts to identify safe and effective maternal nutritional and therapeutic interventions that reduce the risk of offspring developing these congenital malformations. . Genotyping was performed using PCR primers, as described previously (13, 50, 51) .
Histological examination. Hematoxylin and eosin staining and BrdU staining were performed as described previously (13, 52) . Immunohistochemical staining was performed as described previously (53) . Antibodies used for immunohistochemistry were anti-β-spectrin rabbit polyclonal (Abcam) and anti-14-3-3ζ/δ rabbit polyclonal antibodies (Abcam). Fluorescence images were obtained using a fluorescence microscope (model IX71, Olympus). Primary MEPM cells and transfection. Primary MEPM cells were obtained from E13.5 embryos. Briefly, palatal shelves were dissected at E13.5 and trypsinized for 30 minutes at 37°C in a CO2 incubator. After pipetting thoroughly, cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum supplemented with penicillin, streptomycin, l-glutamate, sodium pyruvate, and nonessential amino acids. MEPM cells were treated with or without p38 MAPK inhibitor SB203580 (1 μM), TAK1 inhibitor (5Z)-7-Oxozeaenol (8 nM), or TβRI kinase inhibitor A83-01 (12 nM) for 24 hours. MEPM cells were treated with TGF-β2 (10 ng/ml) for the indicated time. MEPM cells were cultured with NAb for TGF-β2 (2 μg/ml) or TβRIII (2 μg/ml) for 24 hours. pCMV5B-Tgfbr2, HisTgfbr1, or mFRP-Tgfbr3 (addgene) was transiently introduced into MEPM cells using Lipofectamine LTX Plus (Invitrogen) according to standard procedures. The cells were lysed 48 hours later, and then the lysates were analyzed by immunoblotting, as described previously (53) . For 14-3-3ζ/δ, phosphorylated 14-3-3, and β-spectrin staining, MEPM cells were fixed and stained with anti-14-3-3ζ/δ (Abcam), phosphorylated 14-3-3 (Affinity BioReagents), and β-spectrin (Abcam) antibodies as described previously (53) . All fluorescence images were obtained using a fluorescence microscope (model IX71, Olympus). Pictures were taken using MicroSuite Analytical Suite software (Olympus).
Immunological analysis. Immunoblots were performed as described previously (54, 55) . Antibodies used for immunoblotting were as follows: rabbit polyclonal antibodies against TβRII, p38, JNK, phosphorylated JNK, phosphorylated SMAD1/5/8, phosphorylated SMAD1/5, TAK1, phosphorylated TAK1 (Ser412), and TAB1 (all from Cell Signaling Technology); SMAD1/5/8, TRAF6, 14-3-3ζ/δ, TβRI, and FRP-tag (all from Abcam); phosphorylated 14-3-3 (Affinity BioReagents); Lys63-specific ubiquitin (Millipore); BMPRII and 14-3-3ε (both from Santa Cruz Biotechnology Inc.); ACVR2A and ACVR2B (both from Abnova); rabbit monoclonal antibodies against phosphorylated p38 and phosphorylated SMAD2 (both from Cell Signaling Technology); and mouse monoclonal antibodies against SMAD2/3 (BD Biosciences), mouse monoclonal antibodies against SMAD4 and TβRIII (both from Santa Cruz Biotechnology Inc.); mouse monoclonal antibodies against β-spectrin and TGF-β2 (both from Abcam), mouse monoclonal antibody against His-tag (Invitrogen), and mouse monoclonal antibody against GAPDH (Chemicon).
Immunoprecipitation. Extracts in cell lysis buffer containing 10 mM Tris (pH 7.5), 100 mM NaCl, 1% Triton X-100, and protease inhibitor cocktail (Complete, Invitrogen) were lysed by sonication. Lysates containing an equal amount of protein (total volume 1 ml) were centrifuged at 1,000 g for 5 minutes at 4°C to remove debris. The supernatant was precleared with 10 μl pure goat anti-rabbit or anti-mouse IgG gel and specific immobilized antibodies (EY Laboratories Inc.). 10 μl of beads and 2 μg of anti-TβRI, TRAF6 (both from Abcam), TβRIII, β-spectrin (both from Santa Cruz Biotechnology Inc.), TAK1, or His-tag (both from Cell Signaling Technology) antibody were then added to the lysate, and the mixture was rotated for 12 hours at 4°C. The immunoprecipitate/gel complex was washed 5 times with ice-cold cell lysis buffer. The complex was boiled for 5 minutes in SDS sample buffer in the presence of β-mercaptoethanol to elute proteins and centrifuged at 1,000 g for 5 minutes at 4°C. For the ubiquitin assay, cell lysates were heated in the presence of 1% SDS and β-mercaptoethanol to disrupt noncovalent protein-protein interaction and then diluted with lysis buffer (1:10). The supernatant was subjected to SDS-PAGE, transferred to a polyvinylidene difluoride membrane, and analyzed by immunoblotting with indicated antibodies (see the legend for Figure 3) .
Affinity cross-linking. Cells were incubated with I 125 -labeled TGF-β2 (1 ng/ml) in a binding buffer (128 mM NaCl, 5 mM KCl, 1.2 mM CaCl2, 5 mM MgSO4, 50 mM HEPES buffer [pH 7.4]). After incubation for 30 minutes on ice, cross-linker solution (200 μM disuccinimidyl suberate in binding buffer) was added for 30 minutes on ice. The reaction was stopped with a detachment buffer (0.25 M sucrose, 1 mM EDTA, 10 mM Tris buffer [pH 7.4]). The precipitate was dissolved in SDS-PAGE sample buffer, boiled for 5 minutes, and subject to SDS-PAGE analysis.
Quantitative RT-PCR. Total RNA was isolated from mouse embryonic palates dissected at each developmental stage with the QIAshredder and RNeasy Mini extraction kit (QIAGEN), as described previously (54) . PCR primers were purchased from Santa Cruz Biotechnology Inc. Two-tailed Student's t test was applied for statistical analysis of qPCR data. A P value of less than or equal to 0.05 was considered statistically significant. For all graphs, data are represented as mean ± SD.
siRNA transfection. MEPM cells (2 × 10 6 cells) were plated in a 6-well cell culture plate until the cells reached 60%−80% confluence. siRNA duplex and reagents were purchased from Invitrogen and Santa Cruz Biotechnology Inc., respectively. siRNA mixture in transfection medium was incubated with cells for 7 hours at 37°C in a CO2 incubator, as described previously (54) . A total of 5 × 10 3 cells was cultured for 30 minutes with or without TGF-β2 (10 ng/ml).
Palatal shelf organ culture. Timed-pregnant mice were sacrificed at E13.5. Genotyping was carried out as described above. The palatal shelves were microdissected and cultured in serum-free chemically defined medium, as previously described (13) . After 24 hours in culture treated with TAK1 inhibitor (5Z)-7-Oxozeaenol (80 nM), TβRI kinase inhibitor A83-01 (120 nM) or SB431542 (1 μM), p38 MAPK inhibitor SB203580 (10 μM), or NAb for TGF-β2 (20 μg/ml) or TβRIII (20 μg/ml), palates were harvested, fixed in 4% paraformaldehyde/0.1 M phosphate buffer (pH 7.4), and processed. At least 3 samples were analyzed for each experiment. Error bars represent SD.
Whole-mount skeletal staining. The 3-dimensional architecture of the skeleton was examined using a modified whole-mount Alcian blue-Alizarin red S staining protocol, as previously described (13, 54) .
Statistics. Two-tailed Student's t test was applied for statistical analysis. For all graphs, data represent mean ± SD. A P value of less than 0.05 was considered statistically significant.
Study approval. All mouse experiments were conducted in accordance with a protocol approved by the Department of Animal Resources and the Institutional Animal Care and Use Committee of the University of Southern California.
